Publications by authors named "Catherine Faulkes"

The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the seven parameters including three biomarkers routinely assessed in all the newly diagnosed breast cancers (BC), oestrogen receptor (ER), progesterone receptor (PR) and HER-2 and an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2 and KIF23. Taken together, the data are used to produce a molecular subtype for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridisation (ISH) in breast cancer patients.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare different methods for detecting EGFR mutations in tumor samples from patients with non-small cell lung cancer, as these mutations help predict responses to specific treatments.
  • - Eleven laboratories tested coded samples with mutation levels ranging from 0% to 15%, focusing on two key mutations, p.L858R and c.2235_2249del, which are common in about 90% of mutation-positive cases.
  • - Results showed that various techniques like Sanger sequencing and pyrosequencing had better sensitivity than previously reported levels, with a 96% detection rate for samples containing at least 5% mutated DNA, indicating that multiple testing methods are effective for identifying EGFR mutations.
View Article and Find Full Text PDF

We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.

View Article and Find Full Text PDF